Detalles de la búsqueda
1.
Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
Bioorg Med Chem Lett
; 20(8): 2443-7, 2010 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20338758
2.
Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
J Mol Model
; 19(1): 119-30, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22820730
3.
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
J Med Chem
; 55(1): 169-96, 2012 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22148278
4.
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
J Med Chem
; 54(13): 4638-58, 2011 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21604762
Resultados
1 -
4
de 4
1
Próxima >
>>